How effective is crizotinib in treating tumors?

The effect of Crizotinib in treating tumors can be understood from the following studies:

1. Crizotinib study in ALK+ non-small cell lung cancer (NSCLC):

In one study, researchers looked at the effectiveness of crizotinib therapy in 343 patients with ALK+ non-small cell lung cancer that had spread to other parts of the body (metastasis). 172 patients received crizotinib and 171 received chemotherapy. Compare the results of each group. None had been previously treated for metastatic non-small cell lung cancer. Objective response rate (ORR), which measures tumor shrinkage, was also observed in ALK+ tumors. Found 74% of patients responded to crizotinib treatment, while 45% received chemotherapy

Among patients withALK+ NSCLC, those treated with crizotinib were free of tumor growth for a median of 10.9 months (half of the patients were free of tumor growth for more than 10.9 months, and half of the patients were free of tumor growth for less than 10.9 months). For people who received chemotherapy, the median time without tumor growth or spread was seven months. The median duration of tumor response was 11.3 months in the crizotinib group compared with 5.3 months in those who received chemotherapy. Three patients in the crizotinib group had complete responses, meaning all signs of cancer disappeared, while two patients received chemotherapy. In terms of tumor shrinkage, 73% (125/172) of the patients treated with crizotinib had a partial response (their tumors shrank), compared with 44% (75/171) of the chemotherapy group. Patients treated with crizotinib have not been shown to survive significantly longer than those treated with chemotherapy.

2. Crizotinib study in ROS1+ non-small cell lung cancer:

In a small study of 50 patients, researchers looked at the efficacy of crizotinib in patients with ROS1+ non-small cell lung cancer. ROS1+ NSCLC is rarer than ALK+, occurring in only 1% of NSCLC patients. Crizotinib was not compared with chemotherapy. Tumor responses, such as tumor shrinkage, were seen in 66% of people taking crizotinib (overall response rate, or ORR). One patient had a complete response and 64% (32/50) had a partial response. The average duration of both responses was 18.3 months before the tumors grew or spread again.

3. Crizotinib study in ALK+ anaplastic large cell lymphoma (ALCL):

Crizotinib was studied in 26 patients with ALK-positive anaplastic large cell lymphoma (ALCL) who had relapsed or failed to respond to prior therapy. Patients range in age from 3 to 20 years old, with 11 years being the most common age. Overall, 88% of patients responded, with 21 patients (81%) having a complete response and 2 patients (8%) having a partial response. Of the 23 patients who responded, 13 patients (57%) maintained a response at 3 months, 9 patients (39%) maintained a response at 6 months, and 5 patients (22%) maintained a response at 12 months. People responded to treatment in 3.5 to 9.1 weeks. The most common response time is in week 3.9.

4. Research on CrizotinibTreatmentALK-positive inflammatory myofibroblastic tumor (IMT):

Crizotinib is approved for the treatment of ALK-positive (ALK+) inflammatory myofibroblastic tumor in adult and pediatric patients 1 year of age and older who are unresectable, have relapsed, or have failed prior treatment. ALK+IMT are solid growths of soft tissue, usually in the lungs, stomach, or pelvis. Crizotinibwas evaluated in two ALK+IMT multicenter, single-arm, open-label trials in adults and children. In the study, 12 of 14 children (86%) and 5 of 7 adults (71%) experienced an objective response, the primary endpoint. Five (36%) of treated children had a complete response and seven (50%) had a partial response. One adult experienced a complete reaction. The duration of response was at least 6 months in 7 children and at least 12 months in 7 children. In adults, all 5 patients had a DOR of at least 6 months. Responses lasted 12 months or longer in 2 patients. CrizotinibTreatmentALK+IMT was continued until disease progression or unacceptable toxicity.